A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma (Q33344009)

26 July 2017

A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma (English)

1 reference

26 July 2017

A Scott Pierson

1

1 reference

26 July 2017

Peter Gibbs

2

1 reference

26 July 2017

Jon Richards

3

1 reference

26 July 2017

Paul Russ

4

1 reference

26 July 2017

S Gail Eckhardt

5

1 reference

26 July 2017

Rene Gonzalez

6

1 reference

26 July 2017

1 August 2002

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

20

1 reference

26 July 2017

3

1 reference

26 July 2017

357-362

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1016261918256

26 July 2017

0 references

cites work

Phase II trial of carboplatin in patients with advanced melanoma

1 reference

12 December 2020

Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity

1 reference

12 December 2020

Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy

1 reference

12 December 2020

Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents

1 reference

12 December 2020

Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression.

1 reference

12 December 2020

In vitro and in vivo studies on the anticancer activity of dehydroilludin M.

1 reference

12 December 2020

MGI 114: augmentation of antitumor activity when combined with topotecan.

1 reference

12 December 2020

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

1 reference

12 December 2020

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

1 reference

12 December 2020

Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group

1 reference

12 December 2020

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

12 December 2020

A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study

1 reference

12 December 2020

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study

1 reference

12 December 2020

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

1 reference

12 December 2020

Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan

1 reference

12 December 2020

Phase II trial of topotecan in malignant melanoma

1 reference

12 December 2020

Current therapy for malignant melanoma.

1 reference

12 December 2020

Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model

1 reference

12 December 2020

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model

1 reference

12 December 2020

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

1 reference

12 December 2020

In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours

1 reference

12 December 2020

Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1016261918256

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference